Overview

A Safety, Efficacy and Tolerability Study of SEP-225289

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
To determine the safety, efficacy and tolerability of SEP-225289 in subjects with Major Depressive Disorder
Phase:
Phase 2
Details
Lead Sponsor:
Sunovion
Treatments:
Venlafaxine Hydrochloride